MetaCap

Scilex (SCLX) vs Senti Biosciences (SNTI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Senti Biosciences (SNTI) has outperformed Scilex (SCLX) over the past year, losing 8.8% versus a loss of 96.0%. Over five years, SNTI leads with a -98.2% price change compared with -99.7% for SCLX. Senti Biosciences is the larger company by market cap ($4.6 million vs $4.0 million), about 1.2 times the size.

Scilex converts more of its revenue into profit, with a net margin of -1236.4% versus -279263.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

SCLX-95.96%SNTI-8.76%
+51%-26%-103%
Nov 21, 20251 yearNov 20, 2026
SCLX-99.74%SNTI-98.23%
+40%-33%-107%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

SCLX versus SNTI key metrics
MetricSCLXSNTI
Share price$0.5658$1.77
Market cap$3.98M$4.60M
1-day change-12.95%-36.56%
YTD return-92.55%+70.19%
1-year return-95.96%-8.76%
5-year return-99.74%-98.23%
Forward P/E0.78—
EPS (TTM)$-49.70$-46.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$30.25M$22.00K
Revenue growth (YoY)-46.54%—
Net income (latest FY)$-374.05M$-61.44M
Gross margin415.83%—
Operating margin-1143.71%-312631.82%
Net margin-1236.42%-279263.64%
52-week high$14.34$95.04
52-week low$0.50$1.71
Distance from 52-week high-96.05%-98.14%
Analyst consensus—none
Avg. price target upside—+662.71%
Average volume56.11K108.98K
Shares outstanding7.03M2.60M
Employees3439
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SNTI has outperformed SCLX by 87.2 percentage points over the past year.
  • Scilex is more profitable, keeping -1236.4 cents of every revenue dollar as net income versus -279263.6 cents for Senti Biosciences.

About Scilex

SCLX stock →

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 34 employees

About Senti Biosciences

SNTI stock →

Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees

SCLX vs SNTI FAQ

Which is bigger, Scilex or Senti Biosciences?

Senti Biosciences (SNTI) is larger, with a market capitalization of $4.60M compared with $3.98M for Scilex (SCLX).

Which stock has performed better over the past year, SCLX or SNTI?

SNTI returned -8.76% over the past 12 months, compared with -95.96% for SCLX (price return, excluding dividends). Past performance does not predict future results.

Are Scilex and Senti Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons